Inactive Instrument

News Arno Therapeutics Inc(NDA) OTC Bulletin Board

Equities

US0425641042

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2017	Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	CI
2017	Arno Therapeutics Seeks Acquisitions	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University	26/17/26	CI
Arno Therapeutics Seeks Acquisitions	04/17/04	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	15/16/15	CI
Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC	04/16/04	CI
Arno Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	23/16/23	CI
Arno Therapeutics, Inc. Updates Clinical Development of Onapristone Plus Zytiga	16/16/16	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.98 million in funding from a group of investors	15/16/15	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	18/16/18	CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015	31/16/31	CI
Arno Therapeutics, Inc. Appoints Jay Moorin to its Board of Directors	13/16/13	CI
Arno Therapeutics, Inc. announced that it has received $5.28 million in funding from Commercial Street Capital, LLC, and other investors.	12/16/12	CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	17/15/17	CI
Arno Therapeutics, Inc. Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains	21/15/21	CI
Arno Therapeutics, Inc. announced that it expects to receive $2.1 million in funding from Commercial Street Capital, LLC and other investors.	21/15/21	CI
Arno Therapeutics, Inc. Announces Data Demonstrates Novel Antimicrobial Activity of AR-12	20/15/20	CI
Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015	12/15/12	CI
Arno Therapeutics, Inc. Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer	18/15/18	CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015	15/15/15	CI
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12	03/15/03	CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015	16/15/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Arno Therapeutics Inc(NDA) OTC Bulletin Board

Equities

US0425641042

Summary

Filters